Johnson & Johnson (NYSE:JNJ) said that an advisory committee of the EU drug regulator, the European Medicines Agency (EMA), endorsed a label expansion for its and AbbVie’s (NYSE:ABBV) cancer drug, Imbruvica.
The EMA’s Committee for Medicinal Products for Human Use (CHMP) has